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Abstract    
The aim was to study the ability of bioadhesive cyclodextrin-poly(anhydride) 
nanoparticles as carriers for the oral delivery of atovaquone (ATO). In order to 
increase the loading capacity of ATO by poly(anhydride) nanoparticles, the 
following oligosaccharides were assayed: 2-hydroxypropyl--cyclodextrin 
(HPCD), 2,6-di-O-methyl-β-cyclodextrin (DCMD), randomly methylated-β-
cyclodextrin (RMCD) and sulfobuthyl ether-β-cyclodextrin (SBECD). 
Nanoparticles were obtained by desolvation after the incubation between the 
poly(anhydride) with the ATO-cyclodextrin complexes. For the pharmacokinetic 
studies, ATO formulations were administered orally in rats. Overall, ATO 
displayed a higher affinity for methylated cyclodextrins than for the other 
derivatives. However, for in vivo studies, both ATO-DMCD-NP and ATO-HPCD-
NP were chosen. These nanoparticle formulations showed more adequate 
physicochemical properties in terms of size (< 260 nm), drug loading (17.8 and 
16.9 g/mg, respectively) and yield (>75%). In vivo, nanoparticle formulations 
induced higher and more prolonged plasmatic levels of atovaquone than control 
suspensions of the drug in methylcellulose. Relative bioavailability of ATO when 
loaded in nanoparticles ranged from 52% (for ATO-HPCD NP) to 71% (for ATO-
DMCD NP), whereas for the suspension control formulation the bioavailability 
was only about 30%. The encapsulation of atovaquone in cyclodextrins-
poly(anhydride) nanoparticles seems to be an interesting strategy to improve 
the oral bioavailability of this lipophilic drug.  
Keywords 
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Introduction 
Atovaquone is a 1,4-hydroxynaphthoquinone with broadspectrum antiprotozoan 
activity, including demonstrated efficacy against Pneumocystis carinii (Hughes 
et al. 1993), Toxoplasma gondii (Araujo et al. 1991; Kovacks 1992), 
Plasmodium species (Looareesuwan et al. 1996; Radloff et al. 1996), Babesia 
spp. (Matsuu et al. 2004) and Leishmania spp. (Murray and Hariprashad 1996; 
Cauchetier et al. 2002). 
Atovaquone, as a structural analog of ubiquinone, induces a potent inhibitory 
effect in the respiratory chain of parasites (Gutteridge 1991). The site of action 
is believed to be the cytochrome bc1 complex (complex III), in which the drug 
would affect some metabolic enzymes, such as dihydroorotate dehydrogenase 
(Ittarat et al. 1995), that are linked to the mitochondrial electron transport chain 
by ubiquinone. Interestingly, it was demonstrated that the inhibition of 
respiration of mitochondria from protozoan was about 1000-fold more sensitive 
than were mammalian and avian mitochondria (Kessl et al. 2003). 
Atovaquone was proposed as an alternative agent for the treatment of both mild 
and moderate Pneumocystis carinii pneumonia (PCP) in acquired immune 
deficiency syndrome (AIDS) patients and was registered as Mepron® for this 
indication (Sherman 2009). This drug was also found effective against 
toxoplasmosis, another common opportunistic infection in patients with AIDS 
(Spencer and Goa 1995). In this case, atovaquone displays a potent in vitro 
activity against both the tachyzoite and cyst forms of Toxoplasma gondii 
(Romand et al. 1993; Ferguson et al. 1994).  
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Furthermore, atovaquone was also proposed for the treatment of malaria. In 
fact, it was found to be much more active than the standard anti-malarials in 
cultures of Plasmodium falciparum and against P. berghei and P. yoelii in mice 
(Hudson 1993). More interestingly, this antiprotozoan was found curative when 
administered orally in Aotus monkeys infected with P. falciparum (Hudson 
1993). However, when it was used as monotherapy for P. falciparum infections 
there was a 30% treatment failure rate with atovaquone-resistant parasites 
emerging 28 days after treatment (Kessl et al. 2007). To counter this problem it 
has been combined with proglanil hydrochloride (Malarone®) and the 
combination has been found to be effective in areas where parasites are 
resistant to mefloquine, chloroquine, or sulphadoxinepyrimethamine (Kessl et 
al. 2007). Another important advantage of this antiprotozoan is related with its 
tolerability and the absence of severe side effects that would require withdrawal 
of the therapy. The most common reactions are rash, fever, vomiting, diarrhoea, 
abdominal pain and headache (Sherman 2009). 
From a physico-chemical point of view, atovaquone is a highly lipophilic 
substance (Log P= 5) with a poor solubility (<0.2 µg/ml) in aqueous media such 
as gastrointestinal fluids (Dressman and Reppas 2000). Thus, when 
administered orally in a conventional form (i.e. tablet or suspension), this drug is 
irregularly absorbed and it shows a very poor bioavailability. However, 
absorption of ATO can be improved by the simultaneous intake of food (Hughes 
et al. 1991; Rolan et al. 1994). Thus, the oral bioavailability of atovaquone has 
been calculated to be about 23% in the fasted state and 47% in the fed state 
(GlaxoSmithKline 2010). 
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This influence of food in absorption and the high production costs of the drug 
hamper its use in developing countries. Nevertheless atovaquone is now the 
benchmark anti-malarial chemoprophylactic for the traveller market (Sherman 
2009). 
In order to improve the oral bioavailability of atovaquone some different 
attempts have been proposed, including its formulation in self-microemulsifying 
drug delivery systems (Sek et al. 2008), nanocapsules (Sordet et al. 1998; 
Cauchetier et al. 2003) and solid nanoparticles Dearn 2000). Another 
alternative to improve the oral bioavailability of drugs can be the use of 
bioadhesive nanoparticles, such as poly(methylvinylether-co-maleic anhydride) 
or PVM/MA nanoparticles (Arbos et al. 2002). The development of adhesive 
interactions can be of interest to increase the residence time of the drug 
delivery system in close contact with the absorptive membrane. This fact would 
facilitate the establishment of a concentration gradient between the 
pharmaceutical dosage form and the absorptive membrane increasing the 
possibilities for drug absorption. However, in our case, the capability of 
PVM/MA nanoparticles to load highly lipophilic drugs (i.e. atovaquone) is 
limited.  In order to minimise this drawback, one possible solution may be the 
incorporation of cyclodextrins as promoters of drug loading for the preparation 
of nanoparticles. The resulting cyclodextrin-PVM/MA nanoparticles have been 
proven effective to both develop intense bioadhesive interactions between the 
gut (Agüeros et al., 2009a) and to increase the drug loading of lipophilic drugs 
such as paclitaxel (Agüeros et al. 2009b).  
The aim of this work was to study the ability of cyclodextrin-PVM/MA 
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nanoparticles as carriers for the oral delivery of atovaquone. For this purpose, 
the following oligosaccharides were assayed: 2-hydroxypropyl--cyclodextrin, 
randomly methylated β-cyclodextrin, 2,6-di-O-methyl-β-cyclodextrin and 
sulfobuthyl ether-β-cyclodextrin. In addition, the ability of these nanoparticles to 
increase the oral bioavailability of atovaquone was evaluated in laboratory 
animals. 
 
2. Material and methods 
 2.1. Chemicals 
Poly(methylvinyl ether-co-maleic anhydride) or PVM/MA [Gantrez® AN119; MW 
200 000] was kindly gifted by ISP (Barcelona, Spain). Atovaquone (ATO) was 
provided by ChemPacific Corp (Baltimore, USA). 2-hydroxypropyl--
cyclodextrin (HPCD) and randomly methylated β-cyclodextrin (RMCD) were 
purchased from Sigma-Aldrich (Steinheim, Germany), 2,6-di-O-methyl-β-
cyclodextrin (DMCD) from ABCR (Karlsruhe, Germany) and  sulfobuthyl ether-
β-cyclodextrin (SBECD) [Captisol®] from Cydex Inc. (Lenexa, USA). All the 
solvents and reagents used for preparation, characterisation and analysis of 
nanoparticles were of analytical grade and were obtained from Merck 
(Darmstadt, Germany) and Sigma-Aldrich (Steinheim, Germany). All the 
aqueous solutions were prepared using purified distilled water from Millipore 
Milli-Q system (Bedford MA, USA). 
 
2.2. Solubility studies  
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According to Higuchi and Connors method (Higuchi and Connors 1965), 
solubility studies were carried out in aqueous media at 25ºC. The cyclodextrins 
used were HPCD, RMCD, DMCD and SBECD. An excess of ATO was added to 
PBS (0.14 M NaCl, 0.0027 M KCl, 0,01 M phosphate buffer pH 7.4 at 25ºC) 
containing increasing amounts of cyclodextrins. These suspensions were 
shaken under magnetic stirring at 25ºC until solubility equilibrium was reached 
(7 days). Then, the samples were filtered (0.45 µm) and the concentration of 
ATO was determined by UPLC-UV (see section 2.6.2). The presence of trace 
amounts or cyclodextrins did not interfere with the assay. The assays were 
performed in triplicate. 
The apparent stability constant (KC) according to the hypothesis of 1:1 
stoichiometric ratio of complexes was calculated from the phase solubility 
diagrams using the following equation (Higuchi and Connors 1965):  
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        [Eq. 1] 
The slope is obtained from the initial straight-line portion of the plot of 
atovaquone concentration against cyclodextrin concentration, and S0 is the 
equilibrium solubility of atovaquone in the aqueous media. 
 
In addition, the complexation efficiency (CE) was calculated. This parameter is 
determined either from the slope of the phase-solubility profile or the complex to 
free cyclodextrin concentration ratio, which is referred to as the complexation 
efficiency (Loftsson et al. 2005): 
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    [Eq. 2] 
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where [D/CD] is the concentration of dissolved complex, [CD] is the 
concentration of dissolved free cyclodextrin and Slope is the slope of the phase-
solubility profile. 
 
2.3. Preparation of ATO loaded-nanoparticles 
Nanoparticles, containing the atovaquone-cyclodextrin complexes (ATO-CD), 
were prepared by a modification of a solvent displacement method previously 
described (Agüeros et al. 2009a). For this purpose, 20 mg of cyclodextrin and 
2.5 mg of ATO were dissolved in 10 ml of ethanol and maintained under 
agitation for 30 minutes at room temperature. Meanwhile, 100 mg of PVM/MA 
or poly(anhydride) were dissolved in 5 ml of acetone. Then the nanoparticles 
were formed after addition of the ethanol solution containing cyclodextrin and 
ATO to the polymer phase in acetone. After that, 10 ml of desionized water was 
added and the organic solvents were removed under reduce pressure (Büchi R-
14, Switzerland). The resulting carriers were purified by centrifugation at 27,000 
x g for 20 min. The supernatants were removed and the pellets resuspended in 
water. The purification procedure was repeated twice and finally, the 
formulations were frozen and then freeze-dried (Genesis 12EL, Virtis, USA) 
using sucrose (5% w/w) as cryoprotector. 
Empty poly(anhydride) nanoparticles, used as control, were prepared in the 
same way in the absence of ATO. 
 
2.4. Preparation of ATO suspension 
A large amount of 50 mg of ATO was firstly pulverised in a planetary ball-mill 
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(MM200, Restch, Düssedorf, Germany). Then, 5 mg of the resulting powder 
was weighed and homogeneously dispersed under magnetic agitation at room 
temperature in 20 ml of an aqueous solution of methyl cellulose (1% w/v). The 
size of the suspension was assessed by a Zetamaster Analyser system 
(Malvern, UK).  
Before the administration to animals, the amount of drug dispersed in the 
suspension was assessed by Ultra Performance Liquid Chromatography 
(UPLC), (see section 2.6.2). 
 
2.5. Preparation of ATO intravenous solution 
An amount of 3 mg of pulverised ATO was completely dissolved by agitation in 
1 ml of DMSO. Meanwhile, a 5 ml of HPCD solution at a final concentration of 
40% (w/v) was prepared. Then, 100 µl of ATO solution in DMSO were added to 
5 ml of the cyclodextrin preparation. The resulting solution was kept under 
magnetic agitation for 10 minutes and visual inspected to confirm the absence 
of solid particles or agglomerates. Then, the necessary volume of saline (0.9% 
NaCl) was added under agitation to a final volume of 10 ml. Finally, this solution 
was filtered by 0.2 µm PTFE filters (Millipore, Milford, USA) and kept in sealed 
vials till use.  
 
2.6. Characterisation of nanoparticles 
2.6.1. Particle size, zeta potential, morphology and yield 
The size and zeta potential of nanoparticles were measured by photon 
correlation spectroscopy and Laser Doppler Anemometry respectively, using a 
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Zetamaster Analyser system (Malvern Instruments, USA). Size measurements 
were performed at 25ºC and at a 90º scattering angle, and each measurement 
was recorded for 90 s. The mean hydrodynamic diameter was generated by 
cumulative analysis. The zeta potential measurements were performed with an 
aqueous dip cell in the automatic mode. 
The morphology and shape of the nanoparticles were examined by scanning 
electron microscopy (SEM) in a Hitachi S3000-N (Hitachi HTA, Inc., Pleasanton, 
CA, USA). For this purpose freeze-dried formulations were resuspended in 
ultrapure water and centrifuged at 27,000 x g for 20 minutes at 4 ºC. Then, 
supernatants were removed and the obtained pellets were mounted on a glass 
plate, adhered with a double-sided adhesive tape onto metal stubs and coated 
with gold to a thickness of 8 nm (Polaron SC 502, Sputter Coater, UK). The 
micrographs were taken with the following conditions: 10 kV and 50000X from 9 
mm distance. 
The yield of the nanoparticles preparation process was determined by 
gravimetry from freeze-dried nanoparticles as described previously (Arbos et al. 
2002). 
 
2.6.2. Atovaquone content 
The amount of atovaquone loaded into nanoparticles was calculated by UPLC. 
Briefly, the apparatus was an UPLC Acquity with photodiode array detector 
(PDA) set at 254 nm. Data were collected and processed by chromatographic 
software MassLynx 4.1 (Waters). The chromatographic system was equipped 
with a reversed – phase 50 x 2.1 mm UPLC Acquity BEH C18 column (1.7 µm). 
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The gradient elution buffers were A (methanol and 0.1% formic acid) and B 
(water and 0.1% formic acid). The column was eluted with a linear gradient 
consisted of 90% A over 0.5 min, 90 to 10% over 0.5 to 4 min, 10% over 4 to 
4.5 min, returned to 90 for 0.5 min and kept for a further 1 min before the next 
injection. Total run time was 5 min, volume injection was 5 l and the flow rate 
500 l/min. ATO stock solution in methanol was refrigerated and calibration 
curves were designed over the range 0.1–100 µg/ml (r2>0.999). The limit of 
quantification was calculated to be 0.5 µg/ml with a relative standard deviation 
lower than 2.5%. 
For analysis, 5 mg nanoparticles were digested with 1 ml acetonitrile. After 
filtering through 0.2 m PTFE filter, the samples were transferred to auto-
sampler vials, capped and placed in the UPLC auto sampler. Then, 10 µl aliquot 
was injected onto UPLC column. Each sample was assayed in triplicate and 
results were expressed as the amount of atovaquone (in µg) per mg 
nanoparticles. Similarly, the encapsulation efficiency (EE in percentage) was 
calculated as the ratio between the amount of drug entrapped in the 
nanoparticles and the initial amount of ATO used to prepare the nanoparticle 
batch.  
 
2.7. Administration of nanoparticle formulations, oral suspensions and 
intravenous solution to rats 
Male Wistar rats (average weight 225 g) (Harlan, Spain) were housed under 
normal conditions with free access to food and water. The animals were placed 
in metabolic cages and fasted overnight to prevent coprophagia but allowing 
 
free access to water. The experiment was performed according to the policies 
and guidelines of the responsible Committee of the University of Navarra in line 
with the European legislation on animal experiments (86/609/EU). 
For the pharmacokinetics study, the rats were divided at random in five groups 
(n=5). First group received ATO (0.15 mg/kg, 5 ml/kg) by intravenous injection 
through tail vein. The other groups of animals received ATO (2.5 mg/Kg, 10 
ml/kg) in different formulations by oral administration: (a) ATO suspension in 1% 
methyl cellulose; (b) ATO suspension in 1% methyl cellulose containing empty 
nanoparticles; (c) ATO-HPCD complexes loaded in nanoparticles; (d) ATO-
DMCD complexes loaded in nanoparticles. 
Blood samples (~0.1 ml) were collected in tubes containing EDTA (Vacuette® 
EDTA K2) at 0.08, 0.25, 0.5, 1, 2, 5, 10, 24 and 48 h following iv administration 
and 0.25, 0.5, 1, 2, 5, 10, 24, 48 and 96 h following oral administration. The 
volemia was recovered via intraperitoneal with an equal volume of normal saline 
solution preheated at body temperature. Blood samples were immediately 
frozen at -80ºC for posterior analysis. 
 
2.8. Analysis of ATO in blood samples 
2.8.1 Preparation of standard solutions 
A stock solution of ATO was firstly prepared by dissolution of 5 mg ATO in 50 
ml DMSO. Further standard solutions were obtained by serial dilutions with 
DMSO.  The calibration curve samples were prepared by spiking 28.5 µl of rat 
blood with 1.5 µl of the appropriate standard to obtain ATO final concentrations 
of 12.5, 25, 50, 125, 250, 500, 1250 and 2500 ng/ml. All the standard solutions 
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were above the lower limit of quantification and within a linear range of 
quantification. Peak area ratios of the ATO and internal standard were 
calculated and the calibration curves adjusted by fitting these ratios to the 
concentrations by a linear regression method. 
 
2.8.2 Preparation of samples 
Blood samples and calibration standards were treated as follows: 30 µl of 0,1% 
saponin solutions were added to blood and shaken by vortex for 1 min. Protein 
precipitation was carried out after addition of 240 µl of an acetonitrile:methanol 
(1:2) mixture containing internal standard at 50 ng/ml. Then, samples were 
shaken by vortex for 1 minute and centrifuged at 15 000 rpm for 30 min. The 
supernatants were filtered through 0.2 µm filters to avoid the presence of solid 
particles and placed on 300 µl vials to be analysed by LC-MS/MS.  
 
2.8.3. LC-MS/MS Conditions 
UPLC equipment was coupled to API2000 QTrap MS/MS system (Applied 
Biosystems/MDS SCIEX) equipped with an electrospray ionization (ESI) source 
operating with ion spray at -4500 V and heater temperature at 500ºC. Nitrogen 
and zero grade air were employed. Gas settings were as follows: curtain gas 20 
arbitrary units, collision gas 8 arbitrary units, nebulizer gas 40 arbitrary units, 
and heater gas 60 arbitrary units. Dwell time per transition was set at 100 ms. 
Nitrogen was set as curtain gas and collision gas in the Q2 collision cell. Unit 
mass resolution was set in both mass-resolving quadrupole Q1 and Q3. Data 
were processed by Analyst 1.4.1 Software package (MDS SCIEX, Canada). 
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Quantification by multiple reactions monitoring mode (MRM) analysis was 
performed in the negative ion mode. The declustering potential (DP) and the 
collision energy was set at -96 V. The MRM acquisition was performed at unit 
resolution using the transitions m/z 364.9  337.0.  
 
2.9. Pharmacokinetic analysis 
The pharmacokinetic analysis of blood concentration vs time data, obtained 
after administration of the different ATO formulations, was analysed using a 
noncompartmental model with the WinNonlin 5.2 software (Pharsight 
Corporation, Mountain View, US).  
With this purpose, the following pharmacokinetic parameters were estimated 
from data obtained with animals of Group I: Total area under the curve from 
time 0 to ∞ after intravenous administration (AUCiv), clearance (CL), volume of 
distribution in steady state (Vss), mean residence time (MRT) and half-life of the 
terminal phase (t1/2).  
On the other hand, for oral administered formulations, other PK parameters 
were also calculated such as the peak of maximum concentration (Cmax) and 
the time to peak concentration (Tmax). Furthermore, the relative bioavailability (F 
%) of atovaquone was estimated using the ratio of dose-normalised AUC values 
following oral and iv administrations [Eq. 3] 
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    [Eq. 3] 
where Div and Doral are the doses received by intravenous and by oral route 
respectively, and AUCoral and AUCiv are the area under the curve, after the oral 
and intravenous administration. 
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2.10. Statistical analysis 
Data are expressed as the mean ± S.D. of at least three experiments. The 
physico-chemical characteristics were compared using Student’s t-test. For the 
pharmacokinetic studies, the Mann-Withney U-test was used to investigate 
statistical differences. In all cases, p < 0.05 was considered to be statistically 
significant. All data processing was performed using GraphPad Prism 4.0 
statistical software program (GraphPad Software, La Jolla, USA).   
 
3. Results 
3.1. Solubility studies 
Figure 1 shows the phase-solubility diagrams of ATO for the different 
cyclodextrins tested. For all the oligosaccharides, the solubility of the drug in the 
aqueous medium increased linearly as a function of the cyclodextrin 
concentration. The plots obtained for RMCD, HPCD and SBECD were typical of 
those ascribed to AL type diagrams (Higuchi and Connors 1965). In fact, the 
linear host-guest correlations (r > 0.99) suggested the formation of a 1:1 (ATO–
cyclodextrin) complex with respect to cyclodextrin concentrations.  
For the DMCD, the plot appeared to fit better to a BS type diagram.  Hence, in 
order to compare its capacity to enhance the atovaquone solubility with the 
other cyclodextrins, the slope and the complexation efficiency were calculated 
using only the initial ascending portion of the plot, where the concentration of 
cyclodextrin increased linearly with the amount of solubilised drug. 
 
Table 1 summarises the apparent stability constant, Kc, obtained from the slope 
of the linear phase-solubility diagrams. Kc was found to be dependent on the 
nature of the cyclodextrin used. Thus, the higher Kc was observed for DMCD, 
which was found to be about 2-times higher than for HPCD or around 6-fold 
higher than for SBECD. The complexation efficiency constants were calculated 
to be about 0.002, 0.004, 0.006 and 0.010 for SBECD, HPCD, RMCD and 
DMCD respectively.  
 
3.2. Physicochemical characterization of nanoparticles 
Table 2 summarises the main physico-chemical properties of the different 
atovaquone formulations evaluated in this study. For the atovaquone control 
suspension (see section 2.4), the mean size of particles dispersed was found to 
be about 640 nm. In any case, it was calculated that 92% of the drug particles 
were less than 857 nm and 38% were less than 615 nm. Comparing to empty 
nanoparticles (NP), the encapsulation of ATO slightly increased the size of the 
resulting nanoparticles (about 260 nm vs 240 nm, respectively), except when 
HPCD was used (about 200 nm). Interestingly, the polydispersity index (PDI) 
was found to be always lower than 0.2, which is considered as an evidence of a 
homogeneous nanoparticle formulation. The zeta potential of the ATO-loaded 
nanoparticles was found to be slightly less negative than for empty 
nanoparticles (about -46 mV vs -51 mV).  
Figure 2 shows microphotographs of nanoparticles obtained by SEM. In all 
cases, the apparent size of nanoparticles was found to be similar to values 
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obtained by photon correlation spectroscopy. In addition, nanoparticles 
containing ATO displayed a spherical shape and a smooth surface (Figure 2).  
Concerning the drug loading, the amount of ATO encapsulated in nanoparticles 
was found to be dependent on the type of cyclodextrin used. Thus, DMCD and 
HPCD displayed a higher ability to load atovaquone than when RMCD was 
used (around 17 µg/mg vs 12.7 µg /mg, respectively). In the absence of 
cyclodextrins, the amount of ATO loaded in PVM/MA nanoparticles was 
extremely low (below the limit of quantification by UPLC: 0.1 g ATO / mg NP).  
 
3.3. Pharmacokinetic analysis 
The plasma concentration profiles of atovaquone after a single intravenous 
administration at 150 µg /kg formulated in DMSO/HPCD/saline are shown in 
Figure 3. The data were adjusted by non-compartmental model. The peak 
plasma concentration (Cmax) of atovaquone was 525 ± 115 µgml-1. The mean 
values obtained for AUC0- and Vss were 11.1 ± 4.5 µgml-1min-1 and 0.81 ± 0.1 l 
kg-1 respectively. Other pharmacokinetic parameters as clearance and half-life 
(CL = 20.4 ± 7.8 ml h-1 kg-1 and t1/2 = 30.6 ± 13.6 h) showed a slow removal of 
the drug. 
Figure 4 shows the plasma concentration profiles of atovaquone after a single 
oral administration of 2.5 mg/kg to laboratory animals when formulated either in 
nanoparticles or dispersed in a methylcellulose aqueous solution. Table 3 
summarises the main pharmacokinetic parameters derived from these curves. 
The peak blood concentration (Cmax) of atovaquone when loaded in 
nanoparticles with DMCD was found to be significantly higher than when 
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dispersed in the aqueous solution of methylcellulose (p < 0.05), although all the 
formulations appeared to show a similar Tmax. Interestingly, the AUC of 
atovaquone in nanoparticles was about 2.2-fold higher than that in the 
suspension of methylcellulose. Similarly, the MRT of ATO when incorporated in 
nanoparticles was about 5 h longer than when dispersed in the conventional 
formulation.  
Comparing the two nanoparticle formulations, it appears clear that the presence 
of DMCD provided a slightly higher ability than HPCD to promote the absorption 
of this drug. The calculated relative bioavailability of atovaquone delivered in 
nanoparticles was calculated to be about 71% for ATO-DMCD NP and 52% for 
ATO-HPCD NP. In both cases, these values were higher than the bioavailability 
observed for atovaquone when dispersed in the methylcellulose composition 
(about 31%). Finally, it is interesting to note that the incorporation of empty 
nanoparticles to the aqueous dispersion of atovaquone decreased the 
bioavailability of the drug. 
 
4. Discussion  
Atovaquone shows a high activity against several intra- and extracellular 
protozoa (Araujo et al. 1991; Hughes et al. 1993; Matsuu et al. 2004; Murray 
and Hariprashad 1996; Cauchetier et al. 2002) and, associated with proguanil, 
is currently used in malaria prophylaxis and treatment (Pelter and Kain 2005; 
Polhemus et al. 2008). From a biopharmaceutical point of view, atovaquone can 
be classified as a BCS class II, characterised by a high permeability and a low 
aqueous solubility (Dressman and Reppas 2000). In fact, this drug is a highly 
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lipophilic compound that, when administered by the oral route, shows a very 
variable absorption and a poor bioavailability. The dose to solubility ratio (D:S) 
for atovaquone in simulated intestinal fluids has been calculated to be as high 
as 80 liters (Nicolaides et al. 1999). In this context, the selection and design of 
the appropriate drug delivery system has a key influence in the overall efficacy 
of the drug. Thus, for atovaquone, the formulation related factors such as the 
particle radius size or the presence of solubilising agents may be critical to 
modulate its oral absorption.  
Atovaquone was firstly commercialised as tablets (Mepron®), from which it was 
far from a complete oral bioavailability (Nicolaides et al. 1999). It was shown 
that, in the fed state, the absolute bioavailability of Mepron® tablets in HIV 
seropositive volunteers was about 21% (Nicolaides et al. 1999). In 1995, the 
tablet was replaced with the suspension because of the superior bioavailability 
of the latter (Cotton 1995). In different clinical studies, it was confirmed that the 
concentration in plasma reached with a dose in suspension was two to three 
times greater than that reached with the same dose in tablet formulation in the 
fasting or fed state (Hughes et al. 1993; Dixon et al. 1996). This fact was 
explained by the size of atovaquone particles in the suspension which were 
significantly smaller than those produced after tablet disintegration.  
Another key parameter influencing atovaquone absorption is its administration 
with food. Thus, it was demonstrated that, for both the tablet and suspension 
formulations, the atovaquone concentration in plasma is greater when the drug 
is administered with food (Rolan et al. 1994; Dixon et al. 1996). Overall, it has 
been calculated that food increases the bioavailability of atovaquone 1.4-fold 
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over that achieved in a fasting state (Rolan et al. 1994); although, this amount 
can be higher depending on the fat content of the meal (Nicolaides et al. 1999). 
Other possibilities to increase the atovaquone oral bioavailability have been 
proposed, including the development of nanosuspensions (Dearn 2000; 
Nicolaides et al. 1999), self-microemulsifying drug delivery systems (Sek et al. 
2008), liposomes (Cauchetier et al. 2000) or polymer nanocapsules (Dalençon 
et al. 1997; Sordet et al. 1998; Cauchetier et al. 2002). All of these strategies 
are based on an increment of the specific surface area of the atovaquone 
particles and/or its solubility in adequate solvents or micelles to facilitate its 
dispersion in aqueous media.   
Thus, one of the first works to increase the bioavailability of ATO was focused 
on reducing the particle size of the suspension. In this context, Dearn and co-
workers demonstrated in male volunteers that the administration of 
microfluidized suspensions of 1 µm average allowed to increase about 2.6-fold 
the oral relative bioavailability than when a conventional suspensions (of about 
3 µm) was used (Dearn 2000).  In another interesting study, Sek and 
collaborators examined the impact of a range of surfactants on the oral 
bioavailability of lipid based formulations of atovaquone (Sek et al. 2008). No 
differences were observed in beagle dogs when comparing two different self-
microemulsifying drug delivery systems (SMEDDS) comprising long chain 
glycerides, ethanol and either Cremophor EL or Pluronic L121. On the contrary, 
the relative oral bioavailability in dogs of atovaquone was about 3-fold higher 
when incorporated in these SMEDDS than when formulated as aqueous 
suspension.  
 
Another interesting possibility can be the association of this drug with 
bioadhesive nanoparticles. In this case the strategy would be to combine an 
increase of the specific surface area of the drug delivery system with the ability 
of these nanoparticles to develop adhesive interactions within the gut mucosa 
(Agüeros et al. 2009). In this context, our strategy has been the encapsulation 
of atovaquone in PVM/MA nanoparticles by the intervention of cyclodextrins.  
Before the development of the nanoparticles containing atovaquone, the affinity 
of the drug with different cyclodextrins was evaluated. The phase-solubilty 
analysis allowed us to determine not only the affinity between atovaquone and 
cyclodextrin, but also the stechiometry between oligosaccharide and drug. In 
our case, the diagrams mainly showed phase solubility profiles type AL. The 
values of K1:1 obtained for the solubility studies demonstrated that practically all 
the drug in solution would be forming complexes with the different cyclodextrins.  
The CE values confirm the higher affinity of atovaquone for methylated 
cyclodextrins than for other derived beta cyclodextrins (rank order was as 
follows: DMCD>RMCD>HPCD>SBECD). This fact can be explained by the 
higher lipophilicity of methylated cyclodextrins than hydroxypropylated ones 
(Brewster and Loftsson 2007).  
For the preparation of nanoparticles, in a preliminary study, two different 
procedures were tested. First, atovaquone-cyclodextrin complexes were 
incubated with the polymer prior the formation of nanoparticles by desolvation. 
Second, nanoparticles were formed after the incubation of free atovaquone and 
cyclodextrin with the polymer (see Methods). Both procedures yielded 
nanoparticles with similar physico-chemical properties (data not shown) and the 
 
second method was selected for the preparation of atovaquone-loaded 
nanoparticles. These carriers displayed a size ranging from 200 to 260 nm. 
These results are similar to those described for polymer nanocapsules by 
Cauchetier and collaborators (Cauchetier et al. 2003). In this work, they studied 
the influence of different poly(ester) on the physico-chemical properties of 
nanocapsules containing atovaquone dissolved in benzylbenzoate. In this case, 
nanocapsules were produced by interfacial deposition and the encapsulation 
efficiency was slightly higher than those reported here for PVM/MA 
nanoparticles (about 97% vs 80-87%). In any case, these encapsulation 
efficiencies in nanoparticles were higher than those reported for liposomes 
(Cauchetier et al. 2000).  
For in vivo studies, only nanoparticles prepared with DMCD and HPCD were 
used. This selection was based on the physico-chemical properties of 
nanoparticles. Both ATO-HPCD-NP and ATO-DMCD-NP formulations displayed 
high yield and ATO loading values. These formulations were orally administered 
to animals as a single dose of 2.5 mg/kg. As a control, pulverised atovaquone 
was homogeneously dispersed in an aqueous solution of methylcellulose. The 
resulting suspension showed a mean particle diameter of about 640 nm, which 
was smaller than particle sizes previously reported by other research groups 
(Rolan et al. 1994; Dearn 2000; Dixon et al. 1996).  
The pharmacokinetic study was carried out in rats to study the effect of 
nanoparticles formulations on the oral bioavailability of atovaquone. Blood 
samples were taken during the first 24 hours after the administration. Under 
these experimental conditions, the intravenous pharmacokinetic was 
 
characterized by a slow removal of the drug with a long half-life. In previous 
works, it has been suggested that atovaquone is mainly eliminated unchanged 
in bile, suffering from enterohepatic recirculation (Baggish and Hill 2002). This 
fact can explain the presence of a secondary peak in the plasmatic curve of 
atovaquone, 6 hours after administration by the intravenous route (Figure 3). 
On the other hand, all the oral treatments were characterised by an increase of 
the plasmatic drug concentration till the Cmax was obtained, followed by a slow 
decline of atovaquone plasma concentrations. Concerning the Tmax, little 
differences were found; although the highest Tmax was observed for animals 
treated with ATO-DMCD NP. Similarly, Cmax for this formulation was found to be 
significantly higher than for the control suspension (p < 0.05). Overall, 
nanoparticle formulations induced higher and more prolonged plasmatic levels 
of atovaquone than control suspensions. This fact can be explained for ability of 
poly(anhydride) nanoparticles to strongly interact with the gut mucosa, which 
provokes an increase of the residence time and a slower release of the drug in 
the absorption site. On the contrary, the incorporation of empty nanoparticles in 
the atovaquone suspension did not increase the drug bioavailability, which 
confirms the need of an efficient drug encapsulation into the nanoparticles to 
promote the absorption of the antiprotozoan. The calculated relative oral 
bioavailability of atovaquone was found to be between 1.6 and 2.2-times higher 
for nanoparticle formulations than for the control suspension.  
Comparing both types of nanoparticle formulations, carriers prepared in the 
presence of DMCD (ATO-DMCD NP) induced a higher drug bioavailability (70% 
vs 50%) than those prepared with HPCD (ATO-HPCD NP). This fact could be 
 
explained by the higher complex affinity of atovaquone with DMCD than with 
HPCD (see Table 1). Thus, once the ATO-cyclodextrin complex was released in 
the mucosa medium, atovaquone would be dissociated more rapidly from 
HPCD than from DMCD complexes. Under these circumstances, it can be 
hypothesized that a dissociation rate of complexes higher than the absorption 
rate of atovaquone would favour the precipitation of a portion of the released 
drug. A schematic representation of this mechanism is shown in Figure 5. 
 
Conclusions 
The use of cyclodextrins as “promoter” of encapsulation seems to be an 
appropriate strategy to increase the atovaquone loading in poly(anhydride) 
nanoparticles. In addition, the combination between PVM/MA (the copolymer 
between methyl vinyl ether and maleic anhydride) and DMCD (2,6-di-O-methyl-
β-cyclodextrin) enabled us to obtain poly(anhydride) nanoparticles capable of 
offering an atovaquone relative bioavailability close to 72%, which was found to 
be about 2.2 times higher than for the control suspension. 
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Figure captions 
Figure 1. Phase-solubility diagrams of atovaquone-cyclodextrin systems in PBS 
at 25ºC. Data shown the amount of atovaquone ([ATO]) solubilised as a 
function of the amount of cyclodextrin ([CD]) added ( DMCD /  RMCD /  
HPCD /  SBECD). The experiment was performed in triplicate (n = 3). DMCD: 
2,6-di-O-methyl-β-cyclodextrin; RMCD: randomly methylated β-cyclodextrin; 
HPBCD: 2-hydroxypropyl--cyclodextrin; SBECD: sulfobuthyl ether-β-
cyclodextrin. 
 
Figure 2. Microphotographs of ATO-RMCD NP (A), ATO-HPCD NP (B) and 
ATO-DMCD NP (C) obtained by scanning electron microscopy (SEM). 
Magnification: x 25,000. ATO-RMCD NP: ATO-loaded RMCD/poly(anhydride) 
nanoparticles; ATO-HPCD NP: ATO-loaded HPMC/poly(anhydride) 
nanoparticles; ATO-DMCD NP: ATO-loaded DMCD/poly(anhydride) 
nanoparticles. 
 
Figure 3. Pharmacokinetics of atovaquone after an intravenous administration 
to rats. Animals received an intravenous dose of 150 g/kg formulated in 
DMSO/HPCD/saline. Error bars represent standard deviation from the mean 
(n=5).  

Figure 4. Atovaquone plasmatic levels after the oral administration of a single 
dose of 2.5 mg/kg. Animals received the drug  formulated in either nanoparticles 
(ATO-DMCD NP; ,  ATO-HPCD NP; ), 1% methylcellulose suspension (ATO-
 
MC; ) or 1% methylcellulose suspension containing empty nanoparticles 
(ATO-MC+NP; 	). Error bars represent standard deviation from the mean (n=5).  

Figure 5. Representation of the hypothetical mechanism by which the presence 
of DMCD in poly(anhydride) nanoparticles would improve the absorption of 
atovaquone. Kd: dissociation constant; Ka: absorption rate; DMCD:ATO: 
inclusion complex between 2,6-di-O-methyl-β-cyclodextrin and atovaquone. 
HPCD:ATO: inclusion complex between 2-hydroxypropyl--cyclodextrin and 
atovaquone. 
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Table 1. Phase-solubility study: slope of curves, solubility of atovaquone in 
aqueous phosphate buffer containing 10% w/v cyclodextrin (SCD), apparent 
stability constant (Kc) and complexation efficiency (C.E.).  
Cyclodextrin Slope SCD (µM) Kc (M-1) C.E. 
HPCD 0.004 262.8 3300 0.004 
RMCD 0.006 444.6 5300 0.006 
DMCD 0.010* 520.4 6400 0.010 
SBECD 0.002 76.7 950 0.002 
(*) Slope calculated using the linear portion of the curve. 
 
 
Table 2. Physico-chemical characteristics of the different poly(anhydride) 
nanoparticles. Data expressed as the mean ± SD (n=3). ATO-MC: atovaquone 
dispersed in 1% methylcellulose suspension; NP: empty poly(anhydride) 
nanoparticles; ATO-HPCD NP: ATO-loaded HPMC/poly(anhydride) 
nanoparticles; ATO-RMCD NP: ATO-loaded RMCD/poly(anhydride) 
nanoparticles; ATO-DMCD NP: ATO-loaded DMCD/poly(anhydride) 
nanoparticles. 
 
Size a 
(nm) PDI 
Zeta 
potential b 
(mV) 
Yield c 
(%) 
ATO loading      
(µg ATO/mg NP) 
EE d 
(%) 
ATO-MC 641±6 0.127 - - - - 
NP 240±5 0.165 -51.1±3.2 82.05 < 0.1 < 0.1 
ATO-HPCD NP 199±3 0.056 -48.1±1.7 77.39 16.9 ± 1.2 82.77 
ATO-RMCD NP 259±2 0.177 -44.3±2.6 69.12 12.74 ± 2.5 77.72 
ATO-DMCD NP 256±3 0.195 -46.6±5.2 78.73 17.82 ± 0.9 87.33 
a Determination of the nanoparticle size (nm) by photon correlation 
spectroscopy. 
b Determination of the zeta potential (mV) by electrophoretic laser Doppler 
anemometry. 
c Percentage of polymer transformed into nanoparticles. 
d EE: Encapsulation efficiency 
 
 
Table 3. Pharmacokinetic parameters of atovaquone in rats for the different 
formulations tested. ATO-MC: atovaquone dispersed in 1% methylcellulose 
suspension; ATO-MC + NP: physical mixture between empty poly(anhydride) 
nanoparticles and 1% methylcellulose suspension; ATO-DMCD NP: ATO-
loaded DMCD/poly(anhydride) nanoparticles; ATO-HPCD NP: ATO-loaded 
HPMC/poly(anhydride) nanoparticles. Animals received a single oral dose of 2.5 
mg/kg. 
 
Formulation Cmax 
a
 
(µg ml-1) 
Tmax b 
(h) 
AUC0-∞ c 
(µg ml-1min-1) 
MRT d 
(h) 
Frel e       
(%) 
ATO-MC 1.36 ± 0.59 14.6 58.87 ± 29.10 31.38 ± 2.06 31.81 
ATO-MC + NP 0.72 ± 0.26 17.4 38.22 ± 9.84 33.65 ± 2.13 20.65 
ATO-HPCD NP 1.90 ± 0.72 15.6 96.79 ± 29.25 36.31 ± 1.90 52.30 
ATO-DMCD NP 2.71 ± 1.22* 18.4 131.91 ± 56.61* 37.09 ± 1.15 71.28 
a
 Peak plasma concentration  
b
 Time to reach Cmax 
c
 Area under the plasma concentration-time curve 
d
 Mean residence time 
e
 Relative oral bioavailability. 
* p<0.05 ATO-DMCD NP vs ATO-MC. Test U – Mann Whitney. 
 
 
 
 
 
